Liu Xiao, Yin Weiwei, Widjaya Andy Samuel, Yang Yueying, Liu Yunhu, Jiang Yanyan
Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201023, China.
Asian J Pharm Sci. 2021 Sep;16(5):633-642. doi: 10.1016/j.ajps.2021.07.003. Epub 2021 Aug 3.
Arsenic trioxide (ATO) combined with all trans retinoic acid (ATRA) is the first choice for the treatment of low and medium risk acute promyelocytic leukemia (APL). Clinical studies reported that the combination of ATO and ATRA could achieve a significant curative effect. However, the retinoic acid syndrome, serious drug resistance and the short half-life which lead to frequent and large dose administration limit the application of ATRA. In addition, the preparations of arsenic are conventional injections and tablets in clinic, which has poor patients' compliance caused by frequent long-term administration and serious side effects. In order to overcome the above limitations, a phospholipid phase separation gel (PPSG) loaded with ATO and ATRA was developed. ATO+ATRA-PPSG (AAP), as a biodegradable sustained-release delivery system, was the first achievement of co-delivery of hydrophilic ATO and lipophilic ATRA with high drug loading which is the main problem in the application of nano preparation. The prepared PPSG displayed high safety and biocompatibility. The drug in PPSG was released slowly and continuously and for up to 10 d, which could reduce the side effects caused by the fluctuation of blood drug concentration and solve the problem of the long treatment cycle and frequent administration. pharmacokinetics depicted that PPSG could improve the bioavailability, decrease the peak concentration, and prolong the t of ATO and ATRA. Particularly, AAP significantly inhibited the tumor volume, extended the survival period of tumor-bearing mice, and promoted the differentiation of APL cells into normal cells. Therefore, ATO+ATRA-PPSG not only could co-load hydrophilic ATO and lipophilic ATRA according to the clinical dosage, but also possessed the sustained-release and long-acting treatment effect which was expected to reduce administration time and ameliorate compliance of patients. Thus, it had great potential for clinical transformation and application.
三氧化二砷(ATO)联合全反式维甲酸(ATRA)是治疗低中危急性早幼粒细胞白血病(APL)的首选方案。临床研究报道,ATO与ATRA联合应用可取得显著疗效。然而,维甲酸综合征、严重耐药性以及导致频繁大剂量给药的短半衰期限制了ATRA的应用。此外,临床上砷制剂为传统注射剂和片剂,因长期频繁给药导致患者依从性差且副作用严重。为克服上述局限性,研发了一种负载ATO和ATRA的磷脂相分离凝胶(PPSG)。ATO+ATRA-PPSG(AAP)作为一种可生物降解的缓释给药系统,是亲水性ATO和亲脂性ATRA高载药量共递送的首个成果,而这是纳米制剂应用中的主要问题。所制备的PPSG显示出高安全性和生物相容性。PPSG中的药物缓慢持续释放长达10天,可减少血药浓度波动引起的副作用,并解决治疗周期长和给药频繁的问题。药代动力学表明,PPSG可提高生物利用度,降低峰浓度,并延长ATO和ATRA的t1/2。特别地,AAP显著抑制肿瘤体积,延长荷瘤小鼠生存期,并促进APL细胞向正常细胞分化。因此,ATO+ATRA-PPSG不仅可根据临床剂量共负载亲水性ATO和亲脂性ATRA,还具有缓释长效治疗效果,有望减少给药次数并改善患者依从性。因此,其具有巨大的临床转化和应用潜力。